Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]-dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F(1) mice

Schlemmer, Richard and Spruss, Thilo and Bernhardt, Guenther and Schoenenberger, Helmut (2000) Does [meso-1,2-bis(2,6-dichloro-4-hydroxyphenyl)ethylenediamine]-dichloro-platinum(II) act as an immune response modifier? Part III: Progressively growing MXT-M-3,2 breast cancer stimulates the proliferation of phagocytes in B6D2F(1) mice. ARCHIV DER PHARMAZIE, 333 (12). pp. 404-414. ISSN 0365-6233, 1521-4184

Full text not available from this repository. (Request a copy)

Abstract

MXT-M-3,2 breast cancer implanted into female B6D2F(1) mice accelerates the growth of an identical second tumor. This process is accompanied by a significant increase of the granulocyte and monocyte numbers in the blood and of the granulocyte and macrophage numbers in the spleen. A significant positive correlation of strong intensity was found between the tumor weight on the one hand and the number of the granulocytes and macrophages on the other hand. The tumor-dependent promotion of the myelopoiesis is explained with a secretion of hematopoietic growth factors, e.g. of the,granulocyte-macrophage-stimulating growth factor (GMCSF), by the breast cancer cells.

Item Type: Article
Uncontrolled Keywords: TUMOR-BEARING MICE; MACROPHAGE-MEDIATED CYTOTOXICITY; MONOCLONAL-ANTIBODY GK1.5; OXIDE SYNTHASE GENE; BONE-MARROW CELLS; MAMMARY-TUMOR; PHOSPHATIDYL SERINE; SUPPRESSOR CELLS; NK CELLS; GRANULOCYTE; murine MXT-M-3,2 breast cancer; phagocyte proliferation; tumor-host-interaction; flow cytometry
Subjects: 600 Technology > 615 Pharmacy
Divisions: Chemistry and Pharmacy > Institute of Pharmacy > Alumni or Retired Professors > Prof. Schönenberger
Depositing User: Dr. Gernot Deinzer
Date Deposited: 14 Mar 2022 06:54
Last Modified: 14 Mar 2022 06:54
URI: https://pred.uni-regensburg.de/id/eprint/41986

Actions (login required)

View Item View Item